Name: The Bridge Project: KI/MIT & DF/HCC Collaborating Across Cancer Challenges
Start: 2024-05-10T10:00:00-04:00
End: 2024-05-10T13:00:00-04:00
Location: KI auditorium, 76-156

$The Bridge Project: KI\/MIT & DF\/HCC Collaborating Across Cancer Challenges$

MIT & DF/HCC researchers are invited to attend talks by past and present Bridge teams and network with new potential Bridge investigators.
About this Event

Join MIT’s Koch Institute and the Dana-Farber/Harvard Cancer Center for a symposium celebrating the collaborative successes from the program’s past 10+ years and exploring new partnership opportunities for future cancer research advances. The event is held in special recognition of the role of Art Gelb and the Gelb family in initiating and supporting the Bridge Project.

Talks by past and present Bridge Project teams will be followed by a catered networking and information event for potential new Bridge investigators.

Potential applicants to the 2024 Bridge Project RFA (opening this June) are strongly encouraged to attend.”

Featured presentations from past Bridge Project teams:

Translating AI lung cancer risk models into the clinic. Regina Barzilay (Koch Institute) and Lecia V. Sequist (Dana-Farber/Harvard Cancer Center and Massachusetts General Hospital).

Targeting minimal residual disease in acute leukemias. Scott Manalis (Koch Institute) and David Weinstock (Merck, formerly Dana-Farber Cancer Center)

Developing Next-Generation Personal Neoantigen-targeting Vaccines for Treatment of Patients with Metastatic Cancer. Catherine Wu (Dana-Farber Cancer Institute) and Bradley Pentelute (Koch Institute).

Quantitative Tumor Oxygen Measurements in Cervical Cancer Patients. Michael Cima (Koch Institute), Greg Ekchian (Stratagen Bio, formerly Koch Institute Robert Cormack (Brigham and Women's Hospital)

Featured presentations from ongoing Bridge Project teams:

Discovery and identification of optimized second-generation human CAR T cells for solid tumors. Marcela Maus (Massachusetts General Hospital) and Michael Birnbaum (Koch Institute)

A rapidly clinically translatable, closed-loop drug delivery system to minimize pharmacokinetic variability and improve clinical outcomes. Douglas Rubinson (Dana-Farber Cancer Institute)

Exploring alveolar macrophages as vehicles for collecting tumor DNA to improve early diagnosis of non-small cell lung cancer. Sangeeta Bhatia (Koch Institute), Lecia Sequist (Massachusetts General Hospital), and Viktor Adalsteinsson (Broad Institute)